Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Rahul Ghosh"


5 mentions found


It has been quite a year for both Eli Lilly and Novo Nordisk given the boom in weight-loss drugs. Shares in Eli Lilly are up around 60% year-to-date, while its Danish counterpart Novo Nordisk has seen a gain of around 50%. At present, both Eli Lilly and Novo Nordisk offer weight loss treatments. Novo Nordisk Novo Nordisk's Wegovy recently made headlines for reducing the risk of heart attacks and strokes by 20% in adults with heart disease and obesity. Aside from Eli Lilly and Novo Nordisk, Pfizer , Johnson & Johnson and AstraZeneca are also developing weight-loss drugs.
Persons: Eli Lilly, Stocks, Rahul Ghosh, Rowe Price, TRP's Ghosh, Eli Lilly's, Ghosh, FactSet, Lilly, Novo Nordisk Novo Nordisk's Wegovy, Elizabeth Field, Squawk, What's, it's, Michael Bloom Organizations: Novo Nordisk, Nordisk, CNBC Pro, U.S . Food, Administration, pharma, Novo Nordisk Novo Nordisk's, Heart Association Scientific, Citi, Pfizer, Johnson, AstraZeneca, Barclays Locations: Danish, U.S, Novo
FactSet data shows that 70% of the 43 analysts covering Snowflake have buy or overweight ratings on the stock. Year-to-date shares in the biotechnology and life sciences equipment manufacturer are down nearly 4%, but Ghosh remains positive. Schneider Electric Elsewhere, French energy management company Schneider Electric is on the radar of Steven Glass, managing director and investment analyst at Pella Funds. "We're very bullish, although it's not as cheap as it used to be on Schneider Electric. Year-to-date, shares in Schneider Electric are up around 28%.
Persons: Karen Kharmandarian, Colette Kress, Warren Buffett, Rahul Ghosh, Rowe Price, Ghosh, Steven Glass, it's, Glass, Schneider Organizations: Big Tech, CNBC Pro, Nvidia, Thematics Asset Management, U.S, Robotics Fund, Berkshire Hathaway, BE Semiconductor Industries, BE Semiconductor, BE, Danaher Corp, Schneider, Pella Funds Locations: China, Snowflake, Danaher, Pella
Rising rates and the possibility of a recession on the horizon have created a "mixed picture" for equity markets, according to one strategist — but several companies can look forward to markedly stronger earnings growth in the next year. "But, if you're looking for significant earnings expansion, I suspect, at a market level, that's probably less likely. The earnings growth rate for the S & P 500 was 3.7% year-on-year – the first quarter with year-on-year growth since the third quarter of 2022, the data showed. "What Eli Lilly is going to do with their weight loss drug is not dependent on whether the rates are 5.2% or 4.8%. "People didn't really talk about [Adobe] — everyone assumed that they were going to be a loser from AI," he said.
Persons: , they're, Rahul Ghosh, Rowe Price, Ghosh, Eli Lilly, Powell, Software Ghosh, — CNBC's Annika Kim Constantino Organizations: Healthcare Healthcare, UnitedHealth Group, Fellow, Food and Drug Administration, Software, Adobe Creative, Adobe Express
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAI could generate services, revenue and profits 'in the next few years': T. Rowe PriceRahul Ghosh of T. Rowe Price explains why he thinks the AI hype is "real and tangible".
Persons: Rowe Price Rahul Ghosh, Rowe Price
"There are basically two stories in the market today," Rahul Ghosh, portfolio specialist, equity division at T. Rowe Price, told CNBC's "Street Signs Asia" on Thursday. Be 'defensively offensive' In this environment, Ghosh said investors should look to be "almost defensively offensive." Stock Ideas One of Ghosh's top stock picks is chip maker Nvidia , which he described as a "clear winner" in the artificial intelligence "arms race." We're talking about slowing from 50% growth rate to 30%, and potentially picking up next year. Are we going to potentially slow down and have a hard landing, a no landing, or a soft landing?
Total: 5